Ultragenyx's DTX301 Gene Therapy Achieves Significant Ammonia Reduction in Positive Phase 3 OTC Study
Summary
Ultragenyx announced positive 36-week data from its Phase 3 Enh3ance study of DTX301, an AAV8 gene therapy for Ornithine Transcarbamylase (OTC) deficiency. The study demonstrated a statistically significant and clinically meaningful 18% reduction in 24-hour plasma ammonia compared to placebo, with the therapy being well-tolerated. This positive Phase 3 readout is a critical de-risking event for the company, especially following the recent 10-K filing which disclosed setbacks for other pipeline candidates, including a Phase 3 failure and an Incomplete Response Letter for another gene therapy. The successful data for DTX301 significantly bolsters Ultragenyx's pipeline and future commercial prospects in rare disease gene therapy. Investors will now watch for the second primary endpoint data on treatment burden reduction, expected in the first half of 2027, and how this program aligns with the company's stated 2027 profitability goals.
At the time of this announcement, RARE was trading at $22.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $18.41 to $42.37. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.